The diagnosis of “secondary progressive MS” has long been thought to mark a shift in the course of the disease from a primarily inflammatory process to a neurodegenerative one. Although the majority of people with…
Read More
You're Reading:
About the Author
This content was compiled by Rocky Mountain MS Center staff members.
More From This Issue:
InforMS: Winter 2022
Hot Topics in MS: What’s New? What’s Next? What Do People Want to Know?
In this issue, we’ve compiled six reports on “hot topics” in the MS world. These topics are based on both input from the Rocky Mountain MS Center medical team, and...
InforMS: Winter 2022
Hot Topics in MS: COVID-19 — Is It Over?
Not Exactly... But Vaccines and Boosters Remain Our Best Defense COVID-19 continues to twist and turn as new variants become more predominant. The BQ1 and BQ1.1 variants have become the...
InforMS: Winter 2022
Hot Topics in MS: Epstein Barr Virus and MS
Over the past several months, there has been increased interest in the relationship between the Epstein Barr Virus and multiple sclerosis. A study conducted by a Harvard University research team...
InforMS: Winter 2022
Hot Topics in MS: Remyelination — Can MS Damage be Repaired?
Repair of MS damage and the potential for the reversal of the effects of MS are always on the minds of doctors, researchers and those living with the disease. Despite...
InforMS: Winter 2022
Hot Topics in MS: Tyrosine Kinases Inhibitors Studied for Treatment of MS
A whole new family of drugs is currently being studied very aggressively for the treatment of MS: Tyrosine kinases Inhibitors. Tyrosine kinases (TYKs) are intracellular enzymes that play a key...
InforMS: Winter 2022
Hot Topics in MS: Stem Cell Treatment in MS
With current disease modifying therapies (DMTs) we have several highly effective treatments that work for many people, but there is a percentage of the population for whom these medications do...
InforMS: Winter 2022
Hot Topics in MS: Biomarkers
A biomarker is any measurable indicator that can reliably and accurately tell us about a biological state or medical condition. As we continue to learn more about MS and utilize...
InforMS: Winter 2022
Rocky Mountain MS Center at University of Colorado Biobank
Biomarkers are biological markers that can be used in diagnosis, selecting treatments, and evaluating treatment responses. Having pre-collected samples is invaluable for this research, and the Biobank ensures that researchers...
InforMS: Winter 2022
Current Biomarker Studies Underway at the Rocky Mountain MS Center at University of Colorado
NfL and GFAP as Measures of Disease Progression Prospective study to evaluate Neurofilament Light (NfL) and glial fibrillary acidic protein (GFAP) as biomarkers for disease progression over time in patients...